You are here

Treatment with a selective oestrogen receptor modulator

Document

Deep vein thrombosis - Treatment with a selective oestrogen receptor modulator Factor

Last reviewed for CCPS 22 December 2008.

Preliminary questions [25635]

40401 there is some evidence that being treated with a selective oestrogen receptor modulator may be a factor in the development of the condition under consideration.

40402 the veteran has been treated with a selective oestrogen receptor modulator at some time.

25113 the veteran was treated with a selective oestrogen receptor modulator within the 90 days before the clinical onset of the condition under consideration.

25994

the veteran was treated with a selective oestrogen receptor modulator within the 90 days before the clinical onset of the condition under consideration for an illness or injury which is identifiable.

26014the veteran has established the causal connection between being treated with a selective oestrogen receptor modulator and VEA service for the clinical onset of deep vein thrombosis.

26015the veteran has established the causal connection between being treated with a selective oestrogen receptor modulator and operational service for the clinical onset of deep vein thrombosis.

or

26016the veteran has established the causal connection between being treated with a selective oestrogen receptor modulator and eligible service for the clinical onset of deep vein thrombosis.

Clinical onset and operational service [26015]

40403the identified illness or injury, for which the veteran was being treated with a selective oestrogen receptor modulator, is causally related to operational service.

Clinical onset and eligible service [26016]

40404the identified illness or injury, for which the veteran was being treated with a selective oestrogen receptor modulator, is causally related to eligible service.